CJC-1295: What the Research Shows

Medically reviewed by Mark Strehlow, MD, Medical Director — November 2026

CJC-1295 is a laboratory-made analogue — a close chemical relative — of growth hormone-releasing hormone (GHRH), the hormone the hypothalamus uses to tell the pituitary to release growth hormone, and it is sold online and prescribed by clinics, usually with ipamorelin, for recovery, sleep, appearance and ageing. The strongest thing the evidence supports is narrower, and belongs to only one of the two molecules sold under the name: tested in people, the long-acting CJC-1295 DAC raised growth hormone and IGF-1 in the blood for days after one injection, in three small studies of about 63 healthy volunteers, mostly given a single injection, none of which measured whether anything about a person’s health changed. The version most US clinics and sellers supply, CJC-1295 without DAC, has no published human study of any kind, and neither does the pair with ipamorelin.

This review is part of our peptide library, which reports the research on popular peptides as it stands, including where it is thin. Our providers prescribe some of the peptides reviewed in this library, and we earn money from that care.

At a glance

FDA status
Not FDA-approved, and outside the FDA’s and HHS’s compounding policies. The FDA’s advisory committee voted against listing it.
Evidence in people
Three studies, about 63 healthy volunteers, of the DAC version only; the version usually sold has none.
The claim you’ve heard
Better sleep, recovery and ageing: the hormone rise was measured in people, those benefits never were.
Doses tested in people
30-250 mcg/kg by injection, DAC version only, mostly once; no study set a dose for either molecule.
Sport
Prohibited at all times as a growth hormone-releasing hormone analogue, class S2.2.4, on WADA’s 2026 and 2027 Lists.

What CJC-1295 is

“CJC-1295” is one name for two different molecules. The FDA, evaluating it in 2024, put that bluntly: “These are two different active moieties (CJC-1295 (free base) and CJC-1295 (DAC) (free base)) and five different BDSs” — bulk drug substances, the raw active ingredients a pharmacy compounds a medicine from, counted separately for each salt form.

CJC-1295 without DAC is a 29-amino-acid peptide: GHRH’s own first 29 amino acids with four substitutions, molecular weight 3,367.95 g/mol. It is also sold as modified GRF(1-29), mod GRF 1-29 and tetra-substituted GRF 1-29, and a doping-control laboratory identified it in a preparation seized by Norwegian police in 2009, so it has been sold under the name since at least 2010.

CJC-1295 DAC is that same core carrying an extra unit — the DAC — which binds covalently to a thiol group on albumin, the most abundant protein in blood, giving it a molecular weight of 3,647.95 g/mol. ConjuChem Biotechnologies developed it, every published human study used it, and it acts for days rather than minutes.

Both are, in the FDA’s words, “analogues of growth hormone releasing hormone (GHRH)”, whose activity “is mediated by their ability to activate GHRH receptors on somatotroph cells in the anterior pituitary gland”: a signal to the pituitary, not a hormone replacement. They still cannot be read across — “the pharmacological profile of the CJC-1295 DAC cannot be extrapolated to CJC-1295 without the DAC modification” — and the FDA identified no pharmacological studies of CJC-1295 free base or acetate at all, nothing establishing whether the molecule most people are given is active. Neither has a United States Pharmacopeia or National Formulary monograph, the standard a pharmacy would work to, and neither is a component of an FDA-approved drug.

The confusion is itself a safety finding. The FDA counted “at least nine different names that have been used over time for these five BDSs” and wrote: “This represents a safety risk for patients as they may be dosed with a different BDS than the physician ordered.” Even the public chemical registry holds the DAC structure under the free base’s name. Beyond compounded injections it is sold as powder “listed for research use only”, usually without saying which form, and in at least seven blends, most often with ipamorelin.

Where it stands with the FDA

Status checked: November 19, 2026.

In plain words: CJC-1295 is not an approved medicine, and it sits outside both federal compounding policies that cover some other peptides — the FDA’s own, and the one HHS announced in October 2026 (HHS is the federal department the FDA belongs to). Its advisory committee voted against adding any of the five forms, and its safety page names serious adverse events associated with the peptide.

As of November 19, 2026, CJC-1295 is not an FDA-approved drug and is not on the FDA’s list of bulk drug substances that can be used in compounding under section 503A. The FDA’s advisory committee voted against adding any of its five forms on December 4, 2024 (13 to 0 for four forms and 12 to 1 for CJC-1295 acetate), it is in none of the categories of the FDA’s interim compounding policies, and it is not one of the peptides in HHS’s October 2026 interim policy. The FDA says it “has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction” and that “Available clinical data are limited.”

A systemic vasodilatory reaction is flushing, warmth and a transient drop in blood pressure, as the trials described it. Section 503A lets a pharmacy compound a medicine for one named patient without it being FDA-approved, but only from an ingredient with a monograph, one that is a component of an FDA-approved drug, or one on a list the FDA makes by rulemaking — and CJC-1295 is none of those.

The FDA’s own review. Two pharmacies nominated CJC-1295 and both withdrew, which the FDA says does “not reflect a determination by FDA regarding the validity of the nomination”; it evaluated all five forms anyway, for growth hormone deficiency, and proposed “not adding” them. Its minutes record one line of discussion: “One member commented on the lack of evidence for effectiveness.” The compounding industry spoke at the meeting; the committee still voted against every form.

What that means for a compounded prescription. The FDA’s guidance says of an ingredient in this position that a drug product compounded from it “is not eligible for the exemptions in section 503A and may violate the FD&C Act”. Its policy of not intending to act against compounders covers only ingredients in its Category 1 list, and CJC-1295 is in no category.

HHS’s draft policy does not reach it. On October 30, 2026, HHS announced a draft interim policy under which it “does not intend to take enforcement action” against a state-licensed pharmacy or licensed physician compounding with one of six peptide ingredients — BPC-157, epitalon, KPV, MOTS-c, semax and TB-500 — when ten conditions are met. CJC-1295 is not among them, nor is it on the agenda of the advisory committee meeting planned before the end of February 2027. The policy is not approval in any case: HHS’s notice says it “does not establish any rights for any person and is not binding on HHS or the public”, and that “Compounded drugs are not FDA-approved, which means FDA does not review their safety, effectiveness, or quality before they are marketed.”

Sport. CJC-1295 is named on the World Anti-Doping Agency’s Prohibited List in class S2.2.4, “Growth hormone releasing factors, including, but not limited to: growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)”, prohibited at all times; everything in that class is a non-Specified Substance. The List does not distinguish the two molecules, and the 2027 List, in force from January 1, 2027, is unchanged.

Claims you’ll see, and why sources disagree

Pages about CJC-1295 contradict each other for three reasons. The two molecules get mixed up: numbers belonging to CJC-1295 DAC are quoted for the version without DAC, or for the pair with ipamorelin. Animal results are read as human ones: the half-life of “roughly 30 minutes” repeated for the no-DAC molecule matches no human measurement; the nearest real number is natural GHRH, detectable in rat plasma up to an hour after injection. No study has set a dose in people for the molecule being sold, so every source extrapolates differently and errors get copied — a result in mice that two 2026 articles attribute to the pair came from a study of ipamorelin alone.

One point applies to the whole page, and it cuts both ways: “not tested in people” is not “doesn’t work”. It is an absence of knowledge: a benefit has not been shown, and equally safety has not been shown.

Claim Level of evidence Verdict
“Most patients lose 10 to 20 pounds of body fat over a full treatment cycle”; “Lean muscle gains of 3 to 8 pounds are typical” Not tested in people No human study of either molecule measured fat, weight or lean mass; the FDA found “no data on effectiveness of any of the substances” for the use it evaluated.
“the stack produces growth hormone pulses 3 to 5 times larger than either compound administered individually” Not tested in people No human study of the combination exists, so there is no combined measurement.
“IGF 1 levels typically rise 20 to 30% above baseline” for the pair Misattributed The real figures are for CJC-1295 DAC alone: “1.5- to 3-fold” after one injection, 44-45% in the pulsatility study.
“Patients consistently report improved sleep quality within the first 1 to 2 weeks”; “improved skin elasticity, reduced fine lines, thicker hair” Not tested in people or animals No study of CJC-1295 measured sleep, skin, hair, nail, wound or tissue repair. One clinic page making a sleep claim says so itself.
“The CJC 1295 and ipamorelin stack carries a mild side effect profile”; “Serious adverse events remain rare in clinical reporting” Tested in people Not established, and understated: injection-site reactions affected about 70% after one injection and everyone given repeat injections.

What the evidence consists of

Tested in people

Two randomized, placebo-controlled trials have been published, both in 2006, both in healthy volunteers, both of CJC-1295 DAC. The amounts are in the dosing section.

Study People Design What happened Funding and limits
Teichman et al. 2006, study 1 42 healthy adults aged 21-61 (35 drug, 7 placebo) Double-blind; one injection under the skin at one of four ascending doses Growth hormone rose “2- to 10-fold for 6 d or more”, IGF-1 “1.5- to 3-fold for 9-11 d”, above the normal range only at the highest amount Drug “manufactured by ConjuChem, Inc.”; a co-author from the company; no health outcome measured
Teichman et al. 2006, study 2 24 healthy adults, four groups of six, one placebo in each Double-blind; two or three injections over two weeks Half-life “5.4-9.2 days”; drug levels 29-70% higher by the day-14 injection; IGF-1 above baseline at day 28 Same company; 49 days end to end; no health outcome measured

Neither trial, as published, gives a confidence interval for the difference from placebo, and the first does not say how many volunteers got each amount, so how precise the figures are cannot be read from them.

Reported in people

Two further studies gave the drug with no comparison group, so their results are reported, not shown. In the second, Sackmann-Sala and colleagues in 2009 found a handful of proteins shifted in stored blood from 11 of the same men, offered as “potential biomarkers” — not a health outcome, and that paper mentions no adverse events.

Study People What was given What happened Limits
Ionescu & Frohman 2006 12 healthy men aged 20-40 One injection; blood sampled every 20 minutes overnight, before and a week after “The frequency and magnitude of GH secretory pulses were unaltered”; trough growth hormone up 7.5-fold, mean up 46%, IGF-1 up 44-45% and inside the normal range in every man No placebo group; blood measures only; NIH-funded

Together they establish that a long-acting GHRH analogue does to blood tests what its design predicts: growth hormone and IGF-1 rise for days, the natural pulsing pattern survives, and levels build up on repeated injections. None of them establishes anything about how a person looks, feels, performs, sleeps or ages. The FDA: “because they did not measure endpoints such as changes in body composition (lean body mass and fat mass) or height velocity, they do not support effectiveness for the treatment of GHD” — growth hormone deficiency, the use it evaluated. No professional society’s guidelines mention it. And because these molecules ask the pituitary to release growth hormone, a working pituitary is needed: “Patients with complete GHD will not respond to GHSs such as the CJC-1295-related BDSs.”

The one trial in patients, stopped and never published

The only time CJC-1295 was given to people with a medical condition was a phase 2 trial in HIV-related lipodystrophy, sponsored by ConjuChem, and its results never appeared in the literature. Its registry record (NCT00267527) gives enrollment as 120, status “Terminated”, no results posted and no reason for stopping; the official title confirms 12 weeks of treatment, the longest exposure recorded in people anywhere.

The rest comes from two internet reports, which the FDA files under “anecdotal cases”: 192 people enrolled on escalating weekly injections; two hours after an eleventh injection one participant had a heart attack confirmed by ECG and died about an hour later, and the attending physician’s most likely explanation was pre-existing symptomless coronary artery disease, not the drug. The FDA states in its own voice that the company “withdrew CJC-1295 DAC from clinical trials in 2006 after the death of a subject involved in a phase 2 trial”. The termination is verified from the registry; the death, the 192 and the schedules are not, and nobody outside the company knows what became of the other participants.

Animal studies

Nearly every animal study used an unspecified form of CJC-1295 DAC, most of the toxicology exists only as conference abstracts, and almost all came from the developer’s own programme. None of it is a finding about people.

The most important result is a dissociation: in rats given one injection, drug and growth hormone peaked together at about 30 minutes, but “plasma GH concentrations returned to baseline levels by 2 hours after the SC injection … whereas plasma CJC-1295 DAC concentrations declined more slowly, remaining detectable up to 72 hours post-injection”. Drug still present does not mean hormone still being released. In newborn mice unable to make GHRH at all, five weeks of injections produced mice “significantly larger than vehicle-treated GHRH KO mice”, with longer leg bones — which says nothing about an adult who makes GHRH normally. Rats and dogs given repeat doses had injection-site damage at every dose.

The genotoxicity work is the least discussed finding here. A 16-hour exposure “caused DNA damage in the pituitary cells” of mice in the laboratory, and eight weeks of injections in mice “induced pituitary DNA damage”. The FDA rests its conclusion on the laboratory signals, which “demonstrate the genotoxic potential of CJC-1295 DAC-related substances … in mammalian somatotrophs” — the cells that make growth hormone. There are no two-year cancer studies for any of the five forms, and the FDA says they are needed partly because transgenic mice over-producing human GHRH “develop pituitary hyperplasia and tumors”.

CJC-1295 with ipamorelin

The pairing most people are given has no human study at all: searches of the trial registry and the medical literature in November 2026 found none from either side, and the FDA found only market behaviour and one practitioner’s remark about a “‘trending’ synergistic combination”. Combining two substances that stimulate the same axis would be expected to add stimulation; that is theory, measured in nobody.

Dosing: what has been tested and what is reasoned

For the molecule most people are given, nothing has been tested. The FDA searched the medical literature, trial registries and adverse-event databases and found no human data of any kind for CJC-1295 without DAC — no pharmacology, no pharmacokinetics, no safety data, no effectiveness data — and independent searches in November 2026 agree. There is no tested amount at all.

For CJC-1295 DAC the published record is three studies, all in healthy volunteers, all by injection under the skin. The first Teichman trial gave one injection at one of four ascending amounts — 30, 60, 125 and 250 micrograms per kilogram of body weight — and called the drug “relatively well tolerated, particularly at doses of 30 or 60 microg/kg”. The second gave two or three injections over two weeks, at 20, 30 or 60 mcg/kg; Ionescu and Frohman gave 12 men one injection of 60 or 90 mcg/kg. The FDA’s aggregate: “a total of 63 healthy adults (87% of the subjects were men) received up to four SC injections (73% of subjects received one injection) of CJC-1295 DAC (unspecified form) at doses ranging from 30-250 mcg/kg”.

No human study has used any route but injection, though the FDA notes some websites say the peptide “can also be administered as an oral tablet and troche”. For the pair with ipamorelin there is no tested amount at all, and the amounts and schedules in circulation online were set by no study of either molecule.

What the pharmacology implies:

  • Measured in people (DAC only): a half-life of “5.8-8.1 d”, drug measurable “for 10-13 days”, peak growth hormone usually within an hour, IGF-1 still above baseline at day 28 after repeated injections.
  • Claimed and not confirmed: that albumin binding is why the DAC version lasts; the FDA says direct evidence is lacking.
  • Inferred: once given, this is not something that can be stopped and cleared quickly, and tolerance during sustained exposure is possible, since in rats the hormone response ended long before the drug did. IGF-1 is the blood test a prescriber would follow, since approved growth hormone therapy is titrated that way and the top of the tested range pushed healthy volunteers above their normal range — though IGF-1 did not track growth hormone secretion in the study that measured both, so it shows exposure, not how much hormone was released.
  • Theory: the pituitary DNA-damage signal, with no long-term cancer study anywhere, argues against open-ended use; and no interaction study exists, though two mechanisms suggest where to look — anything that changes albumin, and the DPP-4 inhibitor diabetes medicines, which act on the enzyme that breaks down natural GHRH.

There is no dose-finding study in people for either molecule, and no published human exposure beyond 49 days. Where any amount is appropriate, it is a prescriber’s decision for one patient, with that patient’s labs and history in front of them.

Safety, and who should be most cautious

Everything reported in people comes from the three healthy-volunteer studies of CJC-1295 DAC. Injection-site reactions were “the most commonly reported AE” — adverse event — in about 70% after one injection and in every person given repeat injections, with transient hives in nearly 30%. Systemic vasodilatory reactions affected 30% of treated people in the single-dose trial; in the repeat-dose trial flushing occurred only in treated people, within 30 minutes and resolving in one to two hours, in 40% at the lower amounts and 100% at the higher. Heart rate rose with the amount given. Headache affected 63% against 14% on placebo in one trial and 20-80% against 50% in the other, and diarrhoea 43%, reaching 100% at the highest amount. One person had “Transient involuntary leg muscle contractions and some loss of coordination”, and two had transient dizziness with low blood pressure. Apart from the hives, everything was more common at the higher amounts. Blood and urine tests, including blood sugar, and ECGs showed no consistent changes, in studies this small and short. The one death on record came in the stopped trial above.

Adverse-event databases are empty, and that proves nothing: the FDA’s search of its own system found two unusable reports, and products sold for research use sit outside it, so an empty database measures reporting, not safety. The FDA’s concerns, in its words: “we cannot rule out the potential for immunogenicity associated with these impurities and peptide related aggregates”; “Although serious adverse events were not reported in the available clinical studies, these studies were conducted in healthy adults, had small sample sizes, and were of short duration … all of which limits the interpretability of these data”; and “their long-term safety profile in humans is unknown”.

Three further concerns are theory — reasoned rather than observed — and they bear most on anyone with a history of cancer and anyone thinking of taking this for months rather than weeks. The first is tissue growth: the new-growth warning on approved growth hormone labels, the pituitary DNA-damage signal, the absence of long-term cancer studies and the tumour-prone transgenic mice. The second is the immune system: this peptide shares 86% of its sequence with the body’s own GHRH, which “could result in cross reactivity with endogenous GHRH if antibodies to CJC-1295-related BDS were to form”, and the only human antibody data come from volunteers mostly exposed once. The third is the rest of the approved growth hormone warning list, which the FDA applies here because the mechanism is shared: glucose intolerance and diabetes, raised pressure inside the skull, fluid retention, under-active adrenal and thyroid function, and pancreatitis.

Situation What is known Basis
Pregnancy or breastfeeding No human data of any kind; one abstract-only rat study, and nothing measured about transfer into milk No studies exist
Children and under-18s “There is no safety information on the use of any CJC-1295-related BDSs in children” The FDA’s evaluation
A history of cancer No human data; the relevant facts are the new-growth warning on growth hormone labels, the pituitary DNA-damage signal and the missing cancer studies Theory from labels, cells and animals
Known heart disease The trials recorded flushing, transient low blood pressure and a faster heart rate, and the attending physician explained the one reported death by pre-existing symptomless coronary artery disease. The FDA says such events “might inform how the substance should be administered and monitored” in people with heart disease Reported in people; the FDA’s reading
Other medicines No interaction study exists. Two mechanisms suggest where to look: albumin binding, and DPP-4 inhibitor diabetes medicines Theory from mechanism
Tested athletes Prohibited at all times, class S2.2.4, on the 2026 and 2027 Lists WADA’s Prohibited List

Product quality

The FDA’s enforcement records, queried on November 19, 2026, hold seven recalls of compounded CJC-1295 products, every one Class II and every one for sterility assurance or processing controls — nobody could be sure the injectable was sterile or made under control. Four of the seven were CJC-1295 combined with ipamorelin, and the three most recent were initiated on October 19, 2026. That day, five of the seven still had the status “Ongoing”, meaning the FDA had not closed them, and two read “Terminated”; statuses change, so that is one day’s snapshot.

The certificates of analysis are of a piece: for the acetate, one reported 99.0% purity but “no testing result for the control on specified impurities, aggregates, and bioburden/endotoxin levels”, and for an injectable, the FDA notes, “sterility, bacterial endotoxins test (BET), and foreign particulates are critical safety factors”. The free base is also only “slightly water soluble”, so that “it may not be possible to formulate the proposed injectable dosage form at the concentration of 2 mg/mL” — the strength several recalled products are labelled at.

Beyond compounding, the market is largely powders “listed for research use only”, a label that tells a buyer nothing about what is in the bottle and, in the FDA’s letters to sellers, does not shield a product whose marketing shows it is meant for people. A 2026 preprint, not yet peer-reviewed, tested 6,441 samples across fourteen compounds including CJC-1295 and reported “41.6% to 71.1% of samples failed to meet basic quality criteria” depending on the method, with measurable endotoxin in 15%. It gives no figure for CJC-1295 itself, so it describes the market this peptide is sold in, not its purity.

What we make of it

This section is our reading of the evidence above, not a finding from it, and the part our Medical Director reviews most closely.

The molecule question is not a technicality; it is the review. The published human evidence belongs to CJC-1295 DAC, while what is sold and injected as “CJC-1295” in the US is usually the version without DAC, often paired with ipamorelin. Someone given a prescription without being told which molecule it contains may be taking something the research they have read does not describe, and the FDA’s own warning about inconsistent naming says that risk is real.

Where benefit is plausible: a long-acting GHRH analogue does to blood tests what its design predicts, and for the DAC molecule that was measured, not guessed — the natural pulsing pattern survived, unlike with injected growth hormone. Whether moving those numbers in a healthy adult produces anything a person would notice has never been measured. Thin evidence is not evidence of no effect, but it is no reason to expect one either.

What gives us most pause is specific: a DNA-damage signal in the gland being stimulated, with no long-term cancer study; a reasoned possibility of an immune response that could cross-react with a person’s own GHRH; cardiovascular effects in both trials; a death in the only trial that enrolled patients; and seven sterility and processing recalls, three of them weeks old.

None of what would make this reasonable to take exists today: a study of the molecule actually dispensed, one trial measuring an outcome a person cares about, long-term safety data for the pituitary, and a product whose identity and sterility can be verified. Whether it suits anyone, after what testing, with what monitoring and when to stop, are our Medical Director’s to state, and this review leaves them to him.

Peptide care at Rock Creek Wellness

Peptide care here starts with lab testing and a visit with one of our providers, who decides whether any peptide suits you and, if so, which one. It is not a menu: the decision rests on your labs, your history and what the evidence does and doesn’t show. How that works is on our peptide therapy page, and what Peptide Care costs is on the same page.

So that you can weigh this review knowing our interest: RCW’s providers prescribe some of the peptides reviewed in this library, and RCW earns money from that care.

What would change this review

Three things: a human study of the molecule that is actually sold or of the pair with ipamorelin, neither of which is under way; publication of the terminated trial’s data, the only outcome data in patients that exists; and independent confirmation of the pituitary DNA-damage finding.

Common questions

Is CJC-1295 FDA-approved, and can a doctor prescribe it?

It is not FDA-approved, and it is not on the FDA’s list of bulk drug substances that can be used in compounding under section 503A. On prescribers the sources give no yes or no: what they say is that a drug compounded from an ingredient in this position “is not eligible for the exemptions in section 503A and may violate the FD&C Act”.

What is the difference between CJC-1295 with DAC and without?

They are two different molecules. The version without DAC is a 29-amino-acid peptide; the DAC version carries an extra unit that binds to albumin in the blood, and it acts for days rather than minutes. All three published human studies used the DAC version; the one most clinics and sellers supply has never been given in a published study.

Does it raise growth hormone, and would I notice anything?

For CJC-1295 DAC, tested in people, yes to the first: one injection raised growth hormone 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9-11 days. Whether that changes anything a person would notice was never measured — no study of either molecule recorded how people slept, looked, recovered or felt.

Is it safe?

Nobody can say. In the published trials, injection-site reactions, flushing, a faster heart rate and headaches were common, and those trials were small, in healthy adults, and ran at most 49 days. Longer-term safety is unknown, there is none at all in children, and laboratory and animal work found DNA damage in pituitary cells with no long-term cancer studies beside it. The one trial in patients was stopped after a participant died.

Is there a standard dose or schedule?

No study set one for either molecule. The published record is three studies in healthy volunteers given 30-250 mcg/kg by injection, mostly once; for the version usually sold, and for the pair with ipamorelin, there is no tested amount. Where a peptide is appropriate, the amount is a prescriber’s decision for one patient after labs and a visit.

Would it fail a drugs test?

Yes. CJC-1295 is named on WADA’s Prohibited List in class S2.2.4, growth hormone releasing factors, prohibited at all times on both the 2026 and 2027 Lists, with no distinction between the two molecules.

Sources

Show all 14 sourcesHide sources
  1. December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee — FDA Briefing Document for CJC-1295 Related Bulk Drug Substances. US Food and Drug Administration, 2024.
  2. December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee — Minutes. US Food and Drug Administration, 2024.
  3. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks. US Food and Drug Administration, 2026.
  4. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. US Food and Drug Administration, 2025.
  5. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, 2026.
  6. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism, 2006.
  7. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism, 2006.
  8. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone and IGF Research, 2009.
  9. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis, 2010.
  10. ClinicalTrials.gov, CJC-1295 search; NCT00267527, “A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity”. US National Library of Medicine, 2026. Queried November 19, 2026.
  11. openFDA Drug Enforcement Reports API, product_description:”CJC-1295”. US Food and Drug Administration, 2026. Queried November 19, 2026.
  12. Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance. Preprints.org, 2026. Preprint, not peer-reviewed.
  13. FDA Warning Letters database, full-text search “CJC-1295”. US Food and Drug Administration, 2026.
  14. Prohibited List. World Anti-Doping Agency, 2026. The 2026 List, in force to December 31, 2026, and the 2027 List, in force from January 1, 2027.